What is Lu PSMA (Lutetium-Prostate Specific Membrane Antigen) Therapy?

Lu177 PSMA Therapy is a treatment for patients with prostate cancer, especially those who have become refractory to conventional therapy. Lutetium PSMA therapy helps to slow down the growth of the cancer cells, reduce the size of the tumours and most importantly improve the quality of life of the patients by reducing the pain caused by the cancer.

Many prostate cancers, in particular those that have spread or become resistant to hormonal therapies, express a unique receptor on their cell surface called Prostate Specific Membrane Antigen (PSMA). When Prostate Cancer metastasizes i.e. spreads to other parts of the body, the PSMA receptor is expressed over the sites of metastases as well.

How does Lu PSMA Therapy Work?

Lutetium-177 is a radioactive substance that emits beta radiation, a destructive kind of radiation. Lutetium-177 is bound to a small peptide which attaches to the PSMA receptor expressed on the cancer cell surface. The Lutetium 177 – PSMA complex, thus attached to the prostate cancer cell, then emits killing radiation causing cell death of the cancer cell. Since the penetration of the emitted beta particle is very small, the surrounding normal cells are spared.

How is the Therapy Done?

Lu177 PSMA is administered intravenously. The patient is admitted to the hospital for 24 hours. A kidney function scan called a MAG3/EC scan is done prior to the administration of the Lu177 PSMA.

What are the Side Effects of Lu PSMA Therapy?

Lu177 PSMA is well tolerated. The most common side effects are a slightly dry mouth, fatigue and nausea. There may also be a slight fall in the white blood cells and platelets about 2 – 3 weeks after the Lu177 PSMA administration.

What is the Response Rate With Lu PSMA Therapy?

The response rates of Lu177 PSMA depend on the tumour biology of prostate cancer, the initial Gleason Score, the extent of disease and the responses to prior therapies. Typically, more than 70% of patients demonstrate a reduction in S. PSA and a shrinkage of tumours following Lu177 PSMA therapy.

When would the doctor consider using this Therapy?

Lu PSMA Therapy is a very specific therapy and is used for managing metastatic Prostate Cancer or when Prostate Cancer is no longer responsive to other types of treatment.

What are the Treatment Schedules with Lu PSMA Therapy?

Most patients undergo three-four treatment cycles at intervals of 8-12 weeks. The number of cycles and the interim duration may vary between individuals depending on the response and interim assessments.

Why should I choose the nuclear medicine therapy center at Fortis Memorial & Research Institute (FMRI), Gurugram (Haryana, India)?

The Nuclear Medicine Therapy Centre at FMRI was one of the first institutes to offer Radio-ligand Therapy with Lu PSMA, and today, the center receives patients from the country and from across the world.

Beyond Digital PET/CT - Siemens Healthineers Biograph Vision

Summary (10 sec read)

The BEYOND DIGITAL PET/CT - SIEMENS HEALTHINEERS BIOGRAPH VISION is a revolutionary imaging system that redefines precision oncology. It features the world's fastest time of flight, significantly speeding up comprehensive imaging and enhancing workflow efficiency. FlowMotion Technology ensures a seamless and continuous scanning process, improving patient comfort and accuracy. The system's Wholebody Dynamic Imaging and Multiparametric Imaging capabilities provide critical insights into disease progression and molecular-level understanding. With Rapid Wholebody Scanning, the time for a complete scan is drastically reduced, expediting patient care. The BIOGRAPH VISION also reduces radiation dose by 50%, ensuring patient safety. Its 24% larger bore size improves comfort and reduces motion, enhancing image precision. The system's unmatched sensitivity and resolution enable the detection of tiny lesions, as small as two to three millimeters, facilitating early cancer detection and accurate staging. This advanced PET/CT scanner sets new standards in oncology imaging with its precision and efficiency.

Introducing the groundbreaking BEYOND DIGITAL PET/CT - SIEMENS HEALTHINEERS BIOGRAPH VISION, a medical imaging system that sets new standards in precision and efficiency.

In the realm of precision oncology, where even the smallest details hold immense significance, the introduction of advanced digital PET-CT has revolutionized cancer diagnosis. This state-of-the-art imaging system, the BEYOND DIGITAL PET/CT - SIEMENS HEALTHINEERS BIOGRAPH VISION, is far ahead of conventional PET-CT scans, offering a host of exceptional features that have transformed the field of oncology.

Now, let's explore its remarkable benefits:

The BIOGRAPH VISION boasts the world's fastest time of flight, delivering unprecedented scanning speed, reducing the time taken for comprehensive imaging.
Its FlowMotion Technology ensures a seamless and continuous scanning process, enhancing patient comfort while achieving faster and more accurate results.
Wholebody Dynamic Imaging capabilities allow healthcare professionals to visualize dynamic processes within the body, providing crucial insights into disease progression and response to treatment.

Multiparametric Imaging empowers clinicians to evaluate multiple functional parameters simultaneously, enabling a comprehensive understanding of the disease at the molecular level.
With Rapid Wholebody Scanning, the BIOGRAPH VISION significantly reduces the time required for a complete scan, enhancing workflow efficiency and expediting patient care.
Moreover, the system accomplishes this while also decreasing the radiation dose by an impressive 50%, ensuring patient safety and minimizing potential side effects.
The 24% Bigger Bore Size of the machine enhances patient comfort, accommodating individuals of varying sizes, and making the scanning experience less restrictive. This not only improves patient satisfaction but also aids in achieving precise imaging by reducing patient motion during the procedure.
The BIOGRAPH VISION's exceptional capabilities extend to the detection of even the smallest lesions. Its unmatched sensitivity and resolution allow for the precise localization of tiny abnormalities, as small as two to three millimeters, enabling early detection and accurate staging of cancerous lesions.

This advanced digital PET-CT technology proves invaluable in precision oncology. A compelling case study featuring a 63-year-old gentleman with a history of carcinoma prostate exemplifies its impact. Despite conventional PET-CT scans showing no evidence of disease recurrence, the advanced digital PET-CT revealed a tiny focus of intense PSMA uptake in the prostatic bed, precisely localizing the site of relapse. This critical discovery changed the patient's management from surveillance to active treatment, emphasizing the pivotal role of advanced imaging techniques in cancer patient care.

In conclusion, the BEYOND DIGITAL PET/CT - SIEMENS HEALTHINEERS BIOGRAPH VISION represents a transformative leap forward in cancer imaging. Its unparalleled speed, precision, and enhanced capabilities facilitate more accurate diagnoses, personalized treatment plans, and improved patient outcomes. With the ability to capture even the minutest details, this cutting-edge technology is empowering healthcare professionals in the fight against cancer, offering new hope for patients and advancing the field of precision oncology.